MX2021014477A - Nanoemulsion gelificante in situ de brinzolamida. - Google Patents
Nanoemulsion gelificante in situ de brinzolamida.Info
- Publication number
- MX2021014477A MX2021014477A MX2021014477A MX2021014477A MX2021014477A MX 2021014477 A MX2021014477 A MX 2021014477A MX 2021014477 A MX2021014477 A MX 2021014477A MX 2021014477 A MX2021014477 A MX 2021014477A MX 2021014477 A MX2021014477 A MX 2021014477A
- Authority
- MX
- Mexico
- Prior art keywords
- brinzolamide
- nanoemulsion
- situ gelling
- pharmaceutical
- ophthalmic compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se refiere a composiciones farmacéuticas oftálmicas de nanoemulsión gelificante in situ de brinzolamida y/o en combinación con otros ingredientes activos. La invención proporciona composiciones farmacéuticas oftálmicas de nanoemulsión gelificante in situ que comprenden brinzolamida, un aceite disperso en una fase acuosa, un surfactante primario y/o secundario y un espesante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921021265 | 2019-05-29 | ||
PCT/IB2020/055052 WO2020240451A1 (en) | 2019-05-29 | 2020-05-28 | In-situ gelling nanoemulsion of brinzolamide |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014477A true MX2021014477A (es) | 2022-01-06 |
Family
ID=71670310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014477A MX2021014477A (es) | 2019-05-29 | 2020-05-28 | Nanoemulsion gelificante in situ de brinzolamida. |
Country Status (2)
Country | Link |
---|---|
MX (1) | MX2021014477A (es) |
WO (1) | WO2020240451A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116669717A (zh) * | 2020-08-17 | 2023-08-29 | 美国人福制药公司 | 长效原位成型/胶凝组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5378703A (en) | 1990-04-09 | 1995-01-03 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
US6071904A (en) | 1996-12-11 | 2000-06-06 | Alcon Laboratories, Inc. | Process for manufacturing ophthalmic suspensions |
EP3265056A1 (en) * | 2015-03-05 | 2018-01-10 | Allergan, Inc. | Self-emulsifying drug delivery system (sedds) for ophthalmic drug delivery |
US20190008920A1 (en) * | 2017-05-19 | 2019-01-10 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
-
2020
- 2020-05-28 MX MX2021014477A patent/MX2021014477A/es unknown
- 2020-05-28 WO PCT/IB2020/055052 patent/WO2020240451A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2020240451A1 (en) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550622A1 (en) | Kras g12c inhibitors | |
AU2018263868A1 (en) | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies | |
MX2021013581A (es) | Composiciones de nanoemulsiones que comprenden ingredientes biologicamente activos. | |
MX2018009824A (es) | Composiciones para el cuidado personal. | |
MX2019013070A (es) | Composiciones de limpieza mejoradas. | |
MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
MX2019012434A (es) | Agentes inductores de apoptosis. | |
MX2023011657A (es) | Composiciones que comprenden curones y usos de los mismos. | |
MX2018010788A (es) | Composicion oftalmologica. | |
MX2017016517A (es) | Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo. | |
MX2021011297A (es) | Composiciones para el cuidado bucal para el suministro de agente activo. | |
EP4378535A3 (en) | Antibiotic formulations for lower back pain | |
SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
PH12017502322A1 (en) | Therapeutic agent for fibrosis | |
ZA202102702B (en) | Synergistic disinfectant compositions having enhanced antimicrobial efficacy and stability, and methods of using the same | |
MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
PH12021550033A1 (en) | Tumor reduction formulations and methods of use thereof | |
MX2021014477A (es) | Nanoemulsion gelificante in situ de brinzolamida. | |
PH12019502145A1 (en) | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient | |
WO2019107849A3 (ko) | 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트 | |
PH12018000227B1 (en) | A pharmaceutical composition for improving or preventing progression of chronic kidney disease | |
AU2017276588A1 (en) | Physiologically balanced injectable formulations of fosnetupitant | |
MX2018013938A (es) | Emulsion de aceite en agua que contiene harina de trigo y almidon fisicamente modificado. | |
BR112022004677A2 (pt) | Composição oftálmica para o tratamento de uveíte | |
MX2019010618A (es) | Composicion farmacéutica oftálmica, procesos de preparación y usos de las mismas. |